These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17051505)

  • 1. Optimizing resource allocation in United States AIDS drug assistance programs.
    Linas BP; Zheng H; Losina E; Rockwell A; Walensky RP; Cranston K; Freedberg KA
    Clin Infect Dis; 2006 Nov; 43(10):1357-64. PubMed ID: 17051505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving outcomes in state AIDS drug assistance programs.
    Linas BP; Losina E; Rockwell A; Walensky RP; Cranston K; Freedberg KA
    J Acquir Immune Defic Syndr; 2009 Aug; 51(5):513-21. PubMed ID: 19561518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AIDS drug assistance programs and coverage of HIV-related medications.
    Smith SR; Buchanan RJ
    Ann Pharmacother; 2001 Feb; 35(2):155-66. PubMed ID: 11215833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAP faces financial abyss. AIDS Drug Assistance Programs.
    Link D
    GMHC Treat Issues; 1996 Feb; 10(2):11-6. PubMed ID: 11363381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.
    Johri M; David Paltiel A; Goldie SJ; Freedberg KA
    Med Care; 2002 May; 40(5):429-41. PubMed ID: 11961477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment successes draining ADAP resources.
    AIDS Alert; 1998 Aug; 13(8):88. PubMed ID: 11365649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADAP funding seen as insufficient; increases sought.
    AIDS Policy Law; 1997 May; 12(8):6. PubMed ID: 11364308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009.
    Hanna DB; Buchacz K; Gebo KA; Hessol NA; Horberg MA; Jacobson LP; Kirk GD; Kitahata MM; Korthuis PT; Moore RD; Napravnik S; Patel P; Silverberg MJ; Sterling TR; Willig JH; Collier A; Samji H; Thorne JE; Althoff KN; Martin JN; Rodriguez B; Stuart EA; Gange SJ;
    PLoS One; 2013; 8(11):e78952. PubMed ID: 24260137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility policies for the state AIDS drug assistance programs.
    Buchanan RJ; Chakravorty BJ; Smith SR
    Soc Work Health Care; 2001; 32(3):81-104. PubMed ID: 11358274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State implementation of the AIDS drug assistance programs.
    Buchanan RJ; Smith SR
    Health Care Financ Rev; 1998; 19(3):39-62. PubMed ID: 10345412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADAPs remain in crisis as demand grows for new drugs.
    AIDS Policy Law; 1997 Jul; 12(13):3. PubMed ID: 11364512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program.
    Mauskopf JA; Tolson JM; Simpson KN; Pham SV; Albright J
    J Acquir Immune Defic Syndr; 2000 Apr; 23(4):302-13. PubMed ID: 10836752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of State AIDS Drug Assistance Policies on Clinical and Economic Outcomes of People With HIV.
    Snider JT; Goldman DP; Rosenblatt L; Seekins D; Juday T; Sanchez Y; Wu Y; Peneva D; Romley JA
    Med Care Res Rev; 2016 Jun; 73(3):329-48. PubMed ID: 26537525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More patients seek drugs through ADAPs, creating $50 million deficit.
    AIDS Alert; 2001 May; 16(5):53-6. PubMed ID: 11590777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
    Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PPACA and Low-Income People Living with HIV: 2014 Qualified Health Plan Enrollment in a Medicaid Nonexpansion State.
    McManus KA; McGonigle KM; Engelhard CL; Dillingham R
    South Med J; 2016 Jun; 109(6):371-7. PubMed ID: 27255096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD; Keruly JC
    Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence From a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans' Association With Viral Suppression.
    McManus KA; Christensen B; Nagraj VP; Furl R; Yerkes L; Swindells S; Weissman S; Rhodes A; Targonski P; Rogawski McQuade E; Dillingham R
    Clin Infect Dis; 2020 Dec; 71(10):2572-2580. PubMed ID: 31734691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.